Hagop Kantarjian on changing the course of leukemias from mostly incurable to mostly curable
Description
In this episode, 2023 David Karnofsky Memorial Award winner Hagop Kantarjian discusses his long career developing novel therapies for several types of leukemia.
“This is why I consider that choosing leukemia was the best decision in my life,” Kantarjian said to The Cancer Letter. “Because within the span of one professional lifetime, we were able to change the full course of all the leukemias from mostly incurable to mostly curable.”
Reviewing his extensive career in leukemia research, Kantarjian discusses the high cost of drug prices, and his optimism that the U.S. will overcome healthcare disparities, and the many lessons he learned from his mentor, Emil J Freireich.
“It's very important to continue to challenge the standards, the accepted standards, and to try to create new knowledge and innovate outside the general herd mentality that exists at any point in time,” Kantarjian said.
Kantarjian spoke with Jacquelyn Cobb, reporter with The Cancer Letter. A transcript of the conversation appears on The Cancer History Project.
United States
